The chemotherapeutic treatment of advanced Hodgkin's disease

R. Epelbaum; N. Haim; M. Ben-Shahar; I. Valtuch; D. Faraggi; A. Sharabi-Nov; Y. Ben-Arie; Y. Cohen

The chemotherapeutic treatment of advanced Hodgkin's disease

R. Epelbaum, N. Haim, M. Ben-Shahar, I. Valtuch, D. Faraggi, A. Sharabi-Nov, Y. Ben-Arie, Y. Cohen

Department of Statistics

Research output: Contribution to journal › Article › peer-review

Abstract

Between 1972 and 1994, 121 adult patients with advanced Hodgkin's disease received MOPP (M) combination chemotherapy, MOPP alternating with ABVD (M-A) or MOPP and ABV hybrid (M/A). Radiation therapy was given to 1/3 of them. The median age was 35 years, 58% had stage III and 42% had stage IV disease. Failure-free survival at 10 years was 43.9%. It was 66.7%, 48.4% and 29.9% for patients treated by M/A, M-A and M, respectively. Overall survival at 10 years was 40.8%, and 78.2%, 48% and 27.7% for patients treated by M/A, M-A and M, respectively. Multivariate analysis found age (above or below 65 years) and combination chemotherapy (with or without adriamycin) to be significant prognostic factors. M/A combination was more myelotoxic, while M combination caused more second primaries. Today, 80% of patients with advanced Hodgkin's disease may be cured, with low rate of long-term toxicity.

Original language	English
Pages (from-to)	311-315+367
Journal	Harefuah
Volume	140
Issue number	4
State	Published - 2001

Keywords

ABVD
Chemotherapy
Hodgkin's disease
MOPP

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{0cfb8a53bdd84e7a935b7e8d05f1c05d,

title = "The chemotherapeutic treatment of advanced Hodgkin's disease",

abstract = "Between 1972 and 1994, 121 adult patients with advanced Hodgkin's disease received MOPP (M) combination chemotherapy, MOPP alternating with ABVD (M-A) or MOPP and ABV hybrid (M/A). Radiation therapy was given to 1/3 of them. The median age was 35 years, 58% had stage III and 42% had stage IV disease. Failure-free survival at 10 years was 43.9%. It was 66.7%, 48.4% and 29.9% for patients treated by M/A, M-A and M, respectively. Overall survival at 10 years was 40.8%, and 78.2%, 48% and 27.7% for patients treated by M/A, M-A and M, respectively. Multivariate analysis found age (above or below 65 years) and combination chemotherapy (with or without adriamycin) to be significant prognostic factors. M/A combination was more myelotoxic, while M combination caused more second primaries. Today, 80% of patients with advanced Hodgkin's disease may be cured, with low rate of long-term toxicity.",

keywords = "ABVD, Chemotherapy, Hodgkin's disease, MOPP",

author = "R. Epelbaum and N. Haim and M. Ben-Shahar and I. Valtuch and D. Faraggi and A. Sharabi-Nov and Y. Ben-Arie and Y. Cohen",

year = "2001",

language = "English",

volume = "140",

pages = "311--315+367",

journal = "Harefuah",

issn = "0017-7768",

publisher = "Israel Medical Association",

number = "4",

}

TY - JOUR

T1 - The chemotherapeutic treatment of advanced Hodgkin's disease

AU - Epelbaum, R.

AU - Haim, N.

AU - Ben-Shahar, M.

AU - Valtuch, I.

AU - Faraggi, D.

AU - Sharabi-Nov, A.

AU - Ben-Arie, Y.

AU - Cohen, Y.

PY - 2001

Y1 - 2001

N2 - Between 1972 and 1994, 121 adult patients with advanced Hodgkin's disease received MOPP (M) combination chemotherapy, MOPP alternating with ABVD (M-A) or MOPP and ABV hybrid (M/A). Radiation therapy was given to 1/3 of them. The median age was 35 years, 58% had stage III and 42% had stage IV disease. Failure-free survival at 10 years was 43.9%. It was 66.7%, 48.4% and 29.9% for patients treated by M/A, M-A and M, respectively. Overall survival at 10 years was 40.8%, and 78.2%, 48% and 27.7% for patients treated by M/A, M-A and M, respectively. Multivariate analysis found age (above or below 65 years) and combination chemotherapy (with or without adriamycin) to be significant prognostic factors. M/A combination was more myelotoxic, while M combination caused more second primaries. Today, 80% of patients with advanced Hodgkin's disease may be cured, with low rate of long-term toxicity.

AB - Between 1972 and 1994, 121 adult patients with advanced Hodgkin's disease received MOPP (M) combination chemotherapy, MOPP alternating with ABVD (M-A) or MOPP and ABV hybrid (M/A). Radiation therapy was given to 1/3 of them. The median age was 35 years, 58% had stage III and 42% had stage IV disease. Failure-free survival at 10 years was 43.9%. It was 66.7%, 48.4% and 29.9% for patients treated by M/A, M-A and M, respectively. Overall survival at 10 years was 40.8%, and 78.2%, 48% and 27.7% for patients treated by M/A, M-A and M, respectively. Multivariate analysis found age (above or below 65 years) and combination chemotherapy (with or without adriamycin) to be significant prognostic factors. M/A combination was more myelotoxic, while M combination caused more second primaries. Today, 80% of patients with advanced Hodgkin's disease may be cured, with low rate of long-term toxicity.

KW - ABVD

KW - Chemotherapy

KW - Hodgkin's disease

KW - MOPP

UR - http://www.scopus.com/inward/record.url?scp=0034912070&partnerID=8YFLogxK

M3 - Article

C2 - 11303395

AN - SCOPUS:0034912070

SN - 0017-7768

VL - 140

SP - 311-315+367

JO - Harefuah

JF - Harefuah

IS - 4

ER -

The chemotherapeutic treatment of advanced Hodgkin's disease

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this